Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma - Expert Perspectives on AQUILA Phase 3 Trial and FDA Approval

Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.

Explore the evolving landscape of high-risk smoldering myeloma treatment options and the challenges in patient management and risk assessment.